Interscience Conference on Antimicrobial Agents and Chemotherapy. Toronto, ON, CAN, 1997/09.
Antimicrobial resistance in nosocomial isolates is of increasing concern to the clinician, particularly in intensive care units.
With more expensive drugs and prolonged periods of hospitalization required, resistance can result in increased healthcare costs.
For the patient, infection with multiphy resistant strains of bacteria is associated with high mortality rates.
This review focuses on the prevalence of nosocomial infections throughout Europe, with particular emphasis on the prevalence of resistance to common antimicrobial agnets.
The bêta-lactams are the most frequently prescribed antimicrobials, and the growing importance of extended spectrum bêta-lactamases and the hyper-production of chromosomal bêta-lactamase by stably derepressed mutants in the development of microbial resistance are discussed.
Given that the most common reason for modification of an initial empiric antibiotic treatment is the isolation of micro-organisms not susceptible to the initial choice of treatment, the results form two European multicenter trials comparing the efficacy of the carbapenems, meropenem, and imipenem/cilastatin, for the treatment of serious nosocomial infections, are appraised.
In light of these results, it can be concluded that the carbapenems are effective as initial empiric monotherapy for nosocomial infections because of their broad spectrium of efficacy and stability to bêta-lactamases.
Mots-clés Pascal : Etude multicentrique, Résistance multiple, bêta-Lactamase, Hydrolases, Enzyme, Carbapénème dérivé, Infection nosocomiale, Milieu hospitalier, Homme, Prévalence, Epidémiologie, Article synthèse, Europe
Mots-clés Pascal anglais : Multicenter study, Multiple resistance, bêta-Lactamase, Hydrolases, Enzyme, Carbapenem derivatives, Nosocomial infection, Hospital environment, Human, Prevalence, Epidemiology, Review, Europe
Notice produite par :
Inist-CNRS - Institut de l'Information Scientifique et Technique
Cote : 98-0401051
Code Inist : 002B02S02. Création : 25/01/1999.